Abstract
We describe the second case in Europe of verified treatment failure of pharyngeal gonorrhoea, caused by an internationally occurring multidrug-resistant gonococcal clone, with recommended first-line ceftriaxone 250 mg in Slovenia. This is of grave concern since ceftriaxone is last remaining option for empirical treatment. Increased awareness of ceftriaxone failures, more frequent test-of-cure, strict adherence to regularly updated treatment guidelines, and thorough verification/falsification of suspected treatment failures are essential globally. New effective treatment options are imperative.
MeSH terms
-
Adult
-
Anti-Bacterial Agents / therapeutic use*
-
Ceftriaxone / therapeutic use*
-
Drug Resistance, Bacterial
-
Female
-
Gonorrhea / diagnosis
-
Gonorrhea / drug therapy*
-
Gonorrhea / microbiology
-
Heterosexuality
-
Humans
-
Injections, Intramuscular
-
Male
-
Microbial Sensitivity Tests
-
Neisseria gonorrhoeae / drug effects*
-
Neisseria gonorrhoeae / genetics
-
Neisseria gonorrhoeae / isolation & purification*
-
Pharyngeal Diseases / diagnosis
-
Pharyngeal Diseases / drug therapy*
-
Pharyngeal Diseases / microbiology
-
Polymerase Chain Reaction
-
Practice Guidelines as Topic
-
Sequence Analysis, DNA
-
Slovenia
-
Treatment Failure
Substances
-
Anti-Bacterial Agents
-
Ceftriaxone